



Announcement Summary

Entity name

STARPHARMA HOLDINGS LIMITED

Announcement Type

New announcement

Date of this announcement

15/7/2026

The Proposed issue is:

A standard pro rata issue (including non-renounceable or renounceable)

Total number of +securities proposed to be issued for a standard pro rata issue (including non-renounceable or renounceable)

ASX +security code	+Security description	Maximum Number of +securities to be issued
SPL	ORDINARY FULLY PAID	56,123,791

Ex date

17/7/2026

+Record date

20/7/2026

Offer closing date

4/8/2026

Issue date

11/8/2026

Refer to next page for full details of the announcement

For personal use only



Part 1 - Entity and announcement details

1.1 Name of +Entity

STARPHARMA HOLDINGS LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2 Registered Number Type

ABN

Registration Number

20078532180

1.3 ASX issuer code

SPL

1.4 The announcement is

New announcement

1.5 Date of this announcement

15/7/2026

1.6 The Proposed issue is:

A standard +pro rata issue (non-renounceable or renounceable)

1.6a The proposed standard +pro rata issue is:

+ Renounceable

For personal use only



Part 3 - Details of proposed entitlement offer issue

Part 3A - Conditions

3A.1 Do any external approvals need to be obtained or other conditions satisfied before the entitlement offer can proceed on an unconditional basis?

No

Part 3B - Offer details

+Class or classes of +securities that will participate in the proposed issue and +class or classes of +securities proposed to be issued

ASX +security code and description

SPL : ORDINARY FULLY PAID

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?

Existing class

Will the proposed issue of this +security include an offer of attaching +securities?

No

If the entity has quoted company options, do the terms entitle option holders to participate on exercise?

No

Details of +securities proposed to be issued

ASX +security code and description

SPL : ORDINARY FULLY PAID

ISIN Code (if Issuer is a foreign company and +securities do not have +CDIs issued over them)

ISIN Code for the tradable rights created under a renounceable right issue (if Issuer is foreign company and +securities do not have +CDIs issued over them)

Offer ratio (ratio to existing holdings at which the proposed +securities will be issued)

The quantity of additional +securities to be issued

2

For a given quantity of +securities held

15

**What will be done with fractional entitlements?**

Fractions rounded up to the next whole number

Maximum number of +securities proposed to be issued (subject to rounding)

56,123,791

Offer price details for retail security holders**In what currency will the offer be made?**

AUD - Australian Dollar

What is the offer price per +security for the retail offer?

AUD 0.57000

Oversubscription & Scale back details**Will individual +security holders be permitted to apply for more than their entitlement (i.e. to over-subscribe)?**

Yes

Describe the limits on over-subscription

Eligible shareholders who take up their full entitlement may apply for additional New Shares at the Offer Price (defined below) for up to a maximum of 100% of their existing entitlement.

Will a scale back be applied if the offer is over-subscribed?

Yes

Describe the scale back arrangements

Starpharma and the Lead Manager (defined below) retain the flexibility to scale back applications for additional New Shares at their discretion. In the event of a scale back any excess application money will be refunded following allotment. No interest will be paid on any application money received and refunded.

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes

Part 3C - Timetable**3C.1 +Record date**

20/7/2026

3C.2 Ex date

17/7/2026

3C.3 Date rights trading commences

17/7/2026

3C.4 Record date

20/7/2026



3C.5 Date on which offer documents will be sent to +security holders entitled to participate in the +pro rata issue

23/7/2026

3C.6 Offer closing date

4/8/2026

3C.7 Last day to extend the offer closing date

30/7/2026

3C.8 Date rights trading ends

28/7/2026

3C.9 Trading in new +securities commences on a deferred settlement basis

29/7/2026

3C.11 +Issue date and last day for entity to announce results of +pro rata issue

11/8/2026

3C.12 Date trading starts on a normal T+2 basis

12/8/2026

3C.13 First settlement date of trades conducted on a +deferred settlement basis and on a normal T+2 basis

14/8/2026

Part 3E - Fees and expenses

3E.1 Will there be a lead manager or broker to the proposed offer?

Yes

3E.1a Who is the lead manager/broker?

Canaccord Genuity (Australia) Limited ACN 075 071 466

3E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

There is a management fee of 2.0% of the proceeds of the Entitlement Offer.

3E.2 Is the proposed offer to be underwritten?

Yes

3E.2a Who are the underwriter(s)?

Canaccord Genuity (Australia) Limited ACN 075 071 466

3E.2b What is the extent of the underwriting (ie the amount or proportion of the offer that is underwritten)?

The Entitlement Offer is fully underwritten.

3E.2c What fees, commissions or other consideration are payable to them for acting as underwriter(s)?

There is an underwriting fee of 4.0% of the proceeds of the Entitlement Offer.

3E.2d Please provide a summary of the significant events that could lead to the underwriting being terminated

Please refer to the Summary of the Underwriting Agreement provided in Starpharma's Investor Presentation dated 15 July 2026.

3E.2e Is a party referred to in listing rule 10.11 underwriting or sub-underwriting the proposed offer?



No

3E.3 Will brokers who lodge acceptances or renunciations on behalf of eligible +security holders be paid a handling fee or commission?

No

3E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer

Standard share registry, external advisers and ASX administrative fees.

Part 3F - Further Information

3F.1 The purpose(s) for which the entity intends to use the cash raised by the proposed issue

- Complete the first-in-human and dose escalation stages of the DEP® HER2-Lu Phase I study
- Invest in developing and accelerating novel targeted dendrimer-based oncology assets

3F.2 Will holdings on different registers or subregisters be aggregated for the purposes of determining entitlements to the issue?

No

3F.3 Will the entity be changing its dividend/distribution policy if the proposed issue is successful?

No

3F.4 Countries in which the entity has +security holders who will not be eligible to participate in the proposed issue

All countries other than Australia, New Zealand, Hong Kong, Luxembourg, Singapore and United Kingdom.

3F.5 Will the offer be made to eligible beneficiaries on whose behalf eligible nominees or custodians hold existing +securities

Yes

3F.5a Please provide further details of the offer to eligible beneficiaries

Refer to Offer Booklet to be lodged with ASX on Friday 17 July 2026.

3F.6 URL on the entity's website where investors can download information about the proposed issue

www.starpharma.com

3F.7 Any other information the entity wishes to provide about the proposed issue

No.

3F.8 Will the offer of rights under the rights issue be made under a +disclosure document or product disclosure statement under Chapter 6D or Part 7.9 of the Corporations Act (as applicable)?

No

3F.9 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)

For personal use only